
SBMFF
Healthcare · Biotechnology · $11.83B market cap
$0.66500.00 (0.0%)Nov 13, 9:30 AM EST
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Sep 30, 2024
EPS trend, 90 days to now · 30-day revisions 0 up, 0 down
Beat estimates in 2 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Aug 31, 2021 | Time not confirmed | 0.11 | 0.33 | +200.0% |
| May 24, 2021 | Time not confirmed | 0.06 | 0.10 | +66.7% |
| Mar 23, 2021 | Time not confirmed | 0.05 | 0.04 | -20.0% |
| Nov 29, 2020 | After the close | 0.05 | 0.03 | -40.0% |
| Aug 28, 2020 | Time not confirmed | 0.04 | 0.05 | +25.0% |
| May 28, 2020 | Before the open | 0.04 | 0.04 | 0.0% |
| Mar 30, 2020 | Time not confirmed | 0.05 | 0.03 | -40.0% |
| Nov 26, 2019 | Time not confirmed | 0.04 | 0.05 | +25.0% |
| Aug 28, 2019 | Before the open | 0.04 | 0.04 | 0.0% |
| May 21, 2019 | Before the open | 0.05 | 0.05 | 0.0% |
| Mar 31, 2019 | Before the open | 0.04 | 0.03 | -25.0% |
| Nov 21, 2018 | After the close | 0.05 | 0.04 | -20.0% |
| Aug 21, 2018 | After the close | 0.04 | 0.04 |
Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike…
| 0.0% |
| May 18, 2018 | Before the open | 0.07 | 0.07 | 0.0% |
| Mar 22, 2018 | After the close | 0.04 | 0.03 | -25.0% |